multiple sclerosis

Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic
Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic
NPR
drug pricing
generics
MS
multiple sclerosis
Flag link:
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
stem cells
MS
multiple sclerosis
NIH
AHSCT
Biogen
Tysabri
Sanofi
Lemtrada
Roche
Ocrevus
Rituxan
Flag link:
Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study
Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study
Pharmaceutical Business Review
Pear Therapeutics
MS
multiple sclerosis
Pear-006
clinical trials
Flag link:
While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
Endpoints
Novartis
FDA
Gilenya
MS
multiple sclerosis
Mylan
Dr Reddy's
Torrent Pharmaceuticals
Aurobindo
generics
Flag link:
Treating multiple sclerosis with the help of the gut microbiome
Treating multiple sclerosis with the help of the gut microbiome
Fierce Biotech
Brigham and Women's
microbiome
microRNA
multiple sclerosis
MS
Flag link:
Patient charity to pay $4M to settle kickback allegations
Patient charity to pay $4M to settle kickback allegations
Beckers Hospital Review
kickbacks
Medicare
Medicare fraud
MS
multiple sclerosis
Teva Pharmaceutical
Biogen
Novartis
Flag link:
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Fierce Pharma
MS
multiple sclerosis
physicians
Novartis
Mayzent
Merck KGaA
Mavenclad
Biogen
Vumerity
Flag link:
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Multiple Sclerosis News Today
Biogen
MS
multiple sclerosis
Vumerity
drug pricing
Tecfidera
Flag link:
Sanofi pays $315 million to settle Lemtrada go-slow claims
Sanofi pays $315 million to settle Lemtrada go-slow claims
Biopharma Dive
Sanofi
Genzyme
multiple sclerosis
Lemtrada
Flag link:
Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?
Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?
Endpoints
Biogen
Alkermes
FDA
multiple sclerosis
MS
Vumerity
Flag link:
Why People With MS Need Permission from Insurers To Take Life-Saving Drugs. It’s Not The Reason You Think.
Why People With MS Need Permission from Insurers To Take Life-Saving Drugs. It’s Not The Reason You Think.
Forbes
MS
multiple sclerosis
patients
insurers
payers
drug pricing
Flag link:
Acorda loses its last shot at protecting its cash cow franchise drug. It’s up to Inbrija now
Acorda loses its last shot at protecting its cash cow franchise drug. It’s up to Inbrija now
Endpoints
Acorda Therapeutics
AMPYRA
multiple sclerosis
Supreme Court
Flag link:
Sanofi breaks into digital therapeutics with mental health app for MS patients
Sanofi breaks into digital therapeutics with mental health app for MS patients
Fierce Pharma
Sanofi
digital therapeutics
Happyify Health
MS
multiple sclerosis
Flag link:
ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42%
ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42%
Fierce Pharma
Roche
Ocrevus
multiple sclerosis
Flag link:
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Fierce Pharma
Biogen
Tecfidera
MS
multiple sclerosis
Flag link:
Novartis takes aim at Roche's star MS drug
Novartis takes aim at Roche's star MS drug
Reuters
Novartis
Roche
multiple sclerosis
Arzerra
ofatumumab
Ocrevus
Flag link:
Does competition equal lower prices? MS drugs defied cost logic as challengers swarmed in
Does competition equal lower prices? MS drugs defied cost logic as challengers swarmed in
Fierce Pharma
multiple sclerosis
MS
drug pricing
Biogen
Roche
Sanofi
Novartis
Teva Pharmaceutical
Bayer
Flag link:
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
Biopharma Dive
drug pricing
MS
multiple sclerosis
Medicare
Flag link:
5 Biggest New Drugs Approved in 2019 So Far
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Flag link:
Tackling the remaining challenges of multiple sclerosis
Tackling the remaining challenges of multiple sclerosis
Pharmaforum
Merck KGaA
MS
multiple sclerosis
evobrutinib
Flag link:

Pages